Xencor, Inc. (NASDAQ:XNCR) Shares Bought by Aigen Investment Management LP

Aigen Investment Management LP boosted its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 352.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,666 shares of the biopharmaceutical company's stock after buying an additional 37,128 shares during the quarter. Aigen Investment Management LP owned approximately 0.08% of Xencor worth $1,012,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Armistice Capital LLC grew its holdings in shares of Xencor by 65.7% during the third quarter. Armistice Capital LLC now owns 1,478,000 shares of the biopharmaceutical company's stock worth $29,782,000 after purchasing an additional 586,000 shares during the last quarter. Primecap Management Co. CA increased its position in Xencor by 5.6% in the 3rd quarter. Primecap Management Co. CA now owns 8,184,206 shares of the biopharmaceutical company's stock valued at $164,912,000 after acquiring an additional 433,354 shares in the last quarter. Norges Bank bought a new position in shares of Xencor in the fourth quarter worth about $6,909,000. abrdn plc acquired a new position in shares of Xencor during the fourth quarter worth approximately $3,726,000. Finally, Hudson Bay Capital Management LP grew its stake in shares of Xencor by 144.7% during the third quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company's stock valued at $4,685,000 after purchasing an additional 137,500 shares during the last quarter.

Xencor Stock Up 0.1 %

XNCR stock traded up $0.02 during mid-day trading on Tuesday, hitting $23.77. 562,102 shares of the company were exchanged, compared to its average volume of 696,474. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 7.08. Xencor, Inc. has a 1-year low of $16.49 and a 1-year high of $28.96. The firm's 50 day simple moving average is $21.64 and its 200 day simple moving average is $20.93. The firm has a market cap of $1.47 billion, a P/E ratio of -10.85 and a beta of 0.77.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.28). The firm had revenue of $12.80 million during the quarter, compared to analyst estimates of $23.07 million. Xencor had a negative net margin of 82.23% and a negative return on equity of 20.29%. The firm's quarterly revenue was down 32.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.02) EPS. On average, sell-side analysts predict that Xencor, Inc. will post -3.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on XNCR shares. Piper Sandler reiterated a "neutral" rating and issued a $24.00 price objective (down from $37.00) on shares of Xencor in a research report on Wednesday, February 28th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $32.00 target price on shares of Xencor in a research note on Wednesday, February 28th. Mizuho dropped their price target on shares of Xencor from $59.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, January 22nd. BTIG Research decreased their price objective on Xencor from $56.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, April 16th. Finally, StockNews.com raised Xencor from a "sell" rating to a "hold" rating in a research note on Saturday, March 9th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.43.

Insiders Place Their Bets

In other news, CEO Bassil I. Dahiyat sold 12,528 shares of the company's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total transaction of $293,531.04. Following the sale, the chief executive officer now owns 300,097 shares in the company, valued at approximately $7,031,272.71. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Xencor news, CEO Bassil I. Dahiyat sold 12,528 shares of the business's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total transaction of $293,531.04. Following the transaction, the chief executive officer now owns 300,097 shares of the company's stock, valued at $7,031,272.71. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Kurt A. Gustafson sold 14,000 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $23.18, for a total value of $324,520.00. Following the completion of the sale, the director now owns 6,007 shares in the company, valued at approximately $139,242.26. The disclosure for this sale can be found here. Insiders have sold 47,243 shares of company stock valued at $1,103,804 in the last three months. 5.23% of the stock is currently owned by corporate insiders.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.